The anti-tumor efficacy of bladder-cancer-specific OAds: Ad5/F11p-PSCA-UPII-E1A (Cao et al., 2017), Ad/PSCAF/UPII/E1A (Wang et al., 2014b), and KD01 (Guo et al., 2025), was tested using bladder cancer cell lines as monotherapy or in combination with cisplatin. This evidence concerns the gene UPK2 and urinary bladder cancer.